Exercise Metabolic Flexibility in Type 2 Diabetes Treated With Empagliflozin: An Exploratory Analysis of the Randomised Trial EMPA-HEART
Abstract
Aim: Patients with type 2 diabetes (T2D) often develop metabolic inflexibility and reduced exercise capacity. We examined whether sodium-glucose cotransporter 2 inhibitors (SGLT2i) modify substrate oxidation during exercise.
Methods: As a pre-specified exploratory analysis, aimed at understanding the relevance of circulating lipid substrate availability in the effect of empagliflozin on cardiopulmonary function, we measured fasting plasma β-hydroxybutyrate (β(OH)B) and free fatty acids in 44 patients with T2D undergoing cardiopulmonary exercise tests (CPETs) before and after 6 months of randomised therapy with empagliflozin (n = 22) or sitagliptin (n = 22). We used indirect calorimetry to estimate the rates of fat (FATox) and glucose oxidation (CHOox) and identified maximal fat oxidation (MFO) and the exercise intensity at which MFO occurs (FATmax).
Results: After treatment, during low-to-moderate intensity exercise (40% V̇ O2max), FATox increased (+32 [5/65]%, p = 0.02) and CHOox decreased (-30 [-45/-1]%, p = 0.04), in the empagliflozin group only. Also, MFO (empa +0.66 [0/1.31] vs. sita -0.59 [-1.49/0.31] mg/min/kg fat-free mass, p = 0.0249) and FATmax (empa +5 [2/8] vs. sita 0 [-4/3] % V̇ O2max, p = 0.0433) increased in the empagliflozin group. Plasma β(OH)B concentrations increased with empagliflozin (+51 [21/81] μmol/L, p = 0.012) and correlated both with MFO and with FATmax (p 2 at peak exercise) (p < 0.01).
Conclusions: Empagliflozin treatment is associated with…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 44 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.